"Pyrazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterocyclic aromatic organic compounds with the chemical formula C4H4N2.
| Descriptor ID |
D011719
|
| MeSH Number(s) |
D03.383.679
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazines".
Below are MeSH descriptors whose meaning is more specific than "Pyrazines".
This graph shows the total number of publications written about "Pyrazines" by people in this website by year, and whether "Pyrazines" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 1 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 7 | 0 | 7 |
| 2004 | 5 | 1 | 6 |
| 2005 | 13 | 2 | 15 |
| 2006 | 6 | 1 | 7 |
| 2007 | 2 | 11 | 13 |
| 2008 | 11 | 4 | 15 |
| 2009 | 15 | 7 | 22 |
| 2010 | 6 | 8 | 14 |
| 2011 | 14 | 8 | 22 |
| 2012 | 11 | 9 | 20 |
| 2013 | 15 | 9 | 24 |
| 2014 | 13 | 10 | 23 |
| 2015 | 6 | 1 | 7 |
| 2016 | 4 | 7 | 11 |
| 2017 | 9 | 5 | 14 |
| 2018 | 6 | 2 | 8 |
| 2019 | 9 | 2 | 11 |
| 2020 | 4 | 7 | 11 |
| 2021 | 7 | 9 | 16 |
| 2022 | 2 | 9 | 11 |
| 2023 | 1 | 1 | 2 |
| 2024 | 3 | 9 | 12 |
| 2025 | 1 | 4 | 5 |
Below are the most recent publications written about "Pyrazines" by people in Profiles.
-
Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. J Comp Eff Res. 2025 Aug; 14(8):e250035.
-
PIEZO1 Activation-Mediated Generation of Transgene-Free Long-Term Hematopoietic Stem Cells. Am J Hematol. 2025 Jun; 100(6):963-979.
-
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial. JAMA Neurol. 2025 May 01; 82(5):477-485.
-
An in vivo imaging approach for simultaneously assessing tumor response and cytotoxicity-induced tissue response in chemotherapy. Apoptosis. 2025 06; 30(5-6):1515-1524.
-
A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors. Clin Cancer Res. 2025 Jan 06; 31(1):35-44.
-
Effect of voxelotor on cerebral perfusion and cerebral oxygen metabolism and cardiac stress in adult patients with sickle cell disease. Am J Hematol. 2025 Jan; 100(1):78-84.
-
Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial. PLoS Med. 2024 Oct; 21(10):e1004469.
-
Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial). Eur Respir J. 2024 Oct; 64(4).
-
N4-Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses. PLoS Pathog. 2024 Sep; 20(9):e1012574.
-
Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer. Cancer Med. 2024 Sep; 13(17):e70210.